Rinvoq ER 15 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DR26FXMA5
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,189
Award facts
- Contract value 100% obligated
- $12,188.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,188.80 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units) on November 14, 2025, with completion scheduled for November 17, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a prime vendor agreement valued at $999,999,999.00 and extending through December 2026, which provides comprehensive pharmaceutical support for military healthcare programs globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, regularly fulfills defense and veteran healthcare supply requirements through its expansive DLA portfolio. The company's contract awards with DLA demonstrate consistent capability in delivering a broad spectrum of pharmaceutical products across multiple therapeutic domains to support military medical supply chains and other federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. RINVOQ ER (upadacitinib extended-release) is a Janus kinase inhibitor indicated for rheumatoid arthritis and other inflammatory conditions, reflecting the specialized pharmaceutical support AmerisourceBergen provides to federal healthcare beneficiaries.
Quick answers
Who was awarded contract SPE2DR26FXMA5?
SPE2DR26FXMA5 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 14, 2025.
How much is contract SPE2DR26FXMA5 worth?
The government has obligated $12,189 on SPE2DR26FXMA5.
Is contract SPE2DR26FXMA5 an order under another contract?
Yes. SPE2DR26FXMA5 is a delivery order under SPE2DR25D3004, an indefinite delivery contract.
Was contract SPE2DR26FXMA5 competed?
The extent of competition for SPE2DR26FXMA5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award